COMMUNIQUÉS West-GlobeNewswire

Les présentations de Theratechnologies lors de l’IDWeek mettent en évidence l’incidence de l’excès de graisse viscérale abdominale sur le risque de maladie cardiovasculaire chez les personnes vivant avec le VIH
17/10/2024
Selon les données, la tésamoréline pourrait réduire le risque de maladie cardiovasculaire en diminuant l’excès de graisse viscérale abdominale MONTRÉAL, 17 oct. 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (« [...]
Wyatt Surgery Center Selects Nextech Platform for Revenue Cycle Management
17/10/2024
Billing Services Drives Significant Increase in Collections and Cash Flow TAMPA, Fla., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Nextech, market leader of comprehensive technology solutions for specialty physician practices, [...]
AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS
17/10/2024
PRESS RELEASE AB SCIENCE PROVIDES AN UPDATE ON THE APPLICATION FOR CONDITIONAL MARKETING AUTHORISATION OF MASITINIB IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS Paris, 17 October, 2024, 7.30pm CET AB Science SA ( [...]
AB Science fait le point sur la demande d'autorisation de mise sur le marché conditionnelle du masitinib dans la SLA
17/10/2024
COMMUNIQUE DE PRESSE AB SCIENCE FAIT LE POINT SUR LA DEMANDE D'AUTORISATION CONDITIONNELLE DE MISE SUR LE MARCHÉ DU MASITINIB DANS LE TRAITEMENT DE LA SCLÉROSE LATÉRALE AMYOTROPHIQUE Paris, 17 octobre 2024, 19h30 AB [...]
Enlitic Acquires Laitek, Revolutionizing Medical Imaging Data Management
17/10/2024
Enlitic raises AU$22.5M to fund acquisition and ongoing operations Highlights Enlitic’s acquisition of LAITEK advances Enlitic’s strategic roadmap and represents an inflection point for the Company Enlitic has raised AU [...]
OSE Immunotherapeutics Presents New “Cis-Demasking” Bispecific Technology for the Design of Cytokine Drugs with Improved Therapeutic Index
17/10/2024
NANTES, France, October 17, 6:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) , today announced it will be presenting its novel OSE-CYTOMASK Cis-Demasking 1 cytokine technology in oral [...]
OSE Immunotherapeutics présente une nouvelle technologie bispécifique de « Cis-Démasquage » pour la conception de médicaments à base de cytokines avec un indice thérapeutique amélioré
17/10/2024
OSE Immunotherapeutics présente une nouvelle technologie bispécifique de « Cis-Démasquage » pour la conception de médicaments à base de cytokines avec un indice thérapeutique amélioré Nantes, France, le 17 octobre 2024 [...]
EssilorLuxottica: Q3/9M 2024 Revenue - Revenue keeping a solid 4% growth
17/10/2024
Q3/9M 2024 Revenue Revenue keeping a solid 4% growth Group’s revenue up 4.0% at constant exchange rates 1 in Q3, +4.9% year to date Revenue positive in both segments in all the regions in Q3 North America up low-single [...]
EssilorLuxottica: Chiffre d’affaires T3/9M 2024 - Solide croissance du chiffre d'affaires à +4 %
17/10/2024
Chiffre d’affaires T3/9M 2024 Solide croissance du chiffre d'affaires à +4 % Hausse de 4,0 % du chiffre d’affaires à taux de change constants 1 au troisième trimestre, +4,9 % depuis le début de l'année Croissance du [...]
Virbac: Strong revenue growth as of the end of September at +12.6% and +8.6% at constant exchange rates and scope. 2024 targets maintained.
17/10/2024
KEY FIGURES Revenue at the end of September €1 042.1M Growth at constant exchange rates and scope 1 +8.6% including companion animals +11.9% farm animals +3.2% Growth at constant exchange rates 2 +14.0% Overall change + [...]
VIRBAC: Croissance soutenue du chiffre d’affaires à fin septembre de +12,6% et +8,6% à taux de change et périmètre constants. Maintien des objectifs pour 2024.
17/10/2024
CHIFFRES CLÉS Chiffre d’affaires à fin septembre 2024 1 042,1 M€ Croissance à taux de change et périmètre constants 1 +8,6% dont animaux de compagnie +11,9% animaux d’élevage +3,2% Croissance à taux de change constants [...]
Emergex Announces Company Name Change to “Gylden Pharma Limited” Reflecting Company’s Commitment to Advanced Core Technologies and Expanded Product Pipeline
17/10/2024
ABINGDON, United Kingdom, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Emergex Vaccines Holding Limited, a clinical-stage biotechnology company that is addressing major global infectious diseases through the development of [...]
Dr. Wenming Chen to Receive Asian Myeloma Network Distinguished Service Award at the 8th AMN Summit in Seoul
17/10/2024
International Myeloma Foundation (IMF) to hold AMN Awards Ceremony at the 8th AMN Summit in Seoul, South Korea on Saturday, October 19 SEOUL, South Korea, Oct. 17, 2024 (GLOBE NEWSWIRE) -- The International Myeloma [...]
Rapafusyn Pharmaceuticals to Present In Vivo Data on ENT1 Inhibitor for Acute Kidney Injury at the American Society for Nephrology (ASN Kidney Week 2024)
17/10/2024
BALTIMORE, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Rapafusyn Pharmaceuticals, a leader in the field of non-degrading molecular glues, is pleased to announce the upcoming presentation of preclinical in vivo data from its [...]
New Study Reveals Promising Outcomes for Minimally Invasive Sacrospinous Ligament Fixation Using EnPlace® for Treating Pelvic Organ Prolapse in Older Women
17/10/2024
NEWARK, Del., Oct. 17, 2024 (GLOBE NEWSWIRE) -- A new study published last week in the “Journal of Clinical Medicine” has revealed promising results for sacrospinous ligament (SSL) fixation using the EnPlace ® device, a [...]
WellRithms Selected for BenefitsPRO’s 2024 Luminaries Awards
17/10/2024
PORTLAND, Ore., Oct. 17, 2024 (GLOBE NEWSWIRE) -- WellRithms , the industry leading payment integrity firm, has been named to BenefitsPRO Luminaries Class of 2024 in the Rising Star category, one of only two recipients [...]
Avadel Pharmaceuticals Announces FDA Approval of LUMRYZ™ (sodium oxybate) Extended-Release Oral Suspension (CIII) for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Patients 7 Years of Age and Older with Narcolepsy
17/10/2024
-- LUMRYZ is the only FDA-approved once-at-bedtime oxybate treatment for cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy— -- Granted Orphan Drug Exclusivity in [...]
Tevogen Bio Oncology Reports Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion; Forecasts for Non-Oncology Therapeutic Areas to Follow
17/10/2024
Total eligible patients in the US exceed 2 million. Treatment of SARS-CoV-2 infection in solid and hematologic cancer patients under active treatment. Reflects business philosophy of commercial success through patient [...]
TOMI Environmental Solutions, Inc. Announces Record Q3 2024 iHP Corporate Service Revenue
17/10/2024
FREDERICK, Md., Oct. 17, 2024 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc. ® (“TOMI”) (NASDAQ: TOMZ), a global leader in disinfection and decontamination technologies, today announced that its iHP Corporate [...]

Pages